AMEXDRUG CORPORATION

As of June 30, 2013, AMEXDRUG CORPORATION carries a market capitalization of 25.37M, placing it among publicly traded companies globally. Its enterprise value stands at 26.05M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2013, AMEXDRUG CORPORATION has 169.11M shares outstanding.

As of June 30, 2013, AMEXDRUG CORPORATION trades at a trailing price-to-earnings ratio of 153.17. The price-to-sales ratio is 2.77, and the price-to-book ratio stands at 38.54.

As of June 30, 2013, AMEXDRUG CORPORATION trades at an EV/EBITDA multiple of 68.41 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.84 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 78.72 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 26.05M versus a market cap of 25.37M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2013, AMEXDRUG CORPORATION maintains a current ratio of 1.35, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 129.60, indicating elevated leverage, while an interest coverage ratio of 7.98 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2013, AMEXDRUG CORPORATION posted a return on equity (ROE) of 28.78, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 14.81 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 9.02, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.38, useful for judging operating efficiency across full business cycles. The company generates approximately 763,960.25 in revenue per employee across its workforce of 12.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 11.76 indicates how many times AMEXDRUG CORPORATION sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2013, AMEXDRUG CORPORATION recorded 120,226.00 in income tax expense. That works out to an effective tax rate of 42.03, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 286,063.00, leaving 165,837.00 in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on July 10, 2026, AMEXDRUG CORPORATION's stock has gained approximately 100.00% over the past 52 weeks. The 50-day moving average sits at 0.10, while the 200-day moving average is 0.11.

Over the twelve months ended June 30, 2013, AMEXDRUG CORPORATION generated 9.17M in revenue and converted that into 165,837.00 in net income, yielding earnings per share of 0.00. EBITDA reached 380,825.00, while operating income came in at 330,931.00.

As of June 30, 2013, AMEXDRUG CORPORATION holds 168,009.00 in cash and equivalents against 853,092.00 in total debt, resulting in a net debt position of 690,527.00. Total book value stands at 658,233.00, with working capital of 456,846.00 providing operational flexibility.

AMEXDRUG CORPORATION produced -74,833.00 in operating cash flow over the twelve months ended June 30, 2013. After subtracting -460,984.00 in capital expenditures, free cash flow totaled -535,817.00 - equivalent to 0.00 per share.

Over the twelve months ended June 30, 2013, AMEXDRUG CORPORATION posted a gross margin of 13.76, reflecting its pricing power and cost economics. The operating margin of 3.61 and net profit margin of 1.81 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2013. Free cash flow yield is negative at -2.11: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.34, meaning AMEXDRUG CORPORATION raised more capital through share issuance and new debt than it returned via dividends and buybacks.

AMEXDRUG CORPORATION's most recent stock split took place on December 18, 2012 with a 1:20 split ratio.

As of June 30, 2013, AMEXDRUG CORPORATION has an Altman Z-Score of 14.49, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.